Royalty Pharma SG&A Expenses 2019-2024 | RPRX

Royalty Pharma sg&a expenses for the twelve months ending September 30, 2024 were $0.228B, a 13.47% decline year-over-year.

  • Royalty Pharma annual sg&a expenses for 2023 were $0.25B, a 9.87% increase from 2022.
  • Royalty Pharma annual sg&a expenses for 2022 were $0.227B, a 24.33% increase from 2021.
  • Royalty Pharma annual sg&a expenses for 2021 were $0.183B, a 0.61% increase from 2020.

Royalty Pharma SG&A Expenses 2019-2024 | RPRX

  • Royalty Pharma annual sg&a expenses for 2023 were $0.25B, a 9.87% increase from 2022.
  • Royalty Pharma annual sg&a expenses for 2022 were $0.227B, a 24.33% increase from 2021.
  • Royalty Pharma annual sg&a expenses for 2021 were $0.183B, a 0.61% increase from 2020.
Related Stocks
Company NameMarket
Cap
American Express (AXP)$201.2B
Blackstone (BX)$133.5B
Moody's (MCO)$84.9B
Orix Corp Ads (IX)$25.2B
Synchrony Financial (SYF)$24.8B
Brookfield Asset Management (BAM)$24.6B
Grupo Financiero Banorte SAB De CV (GBOOY)$19.9B
SoFi Technologies (SOFI)$15.6B
Jefferies Financial Group (JEF)$15.3B
Equitable Holdings (EQH)$14.6B
Houlihan Lokey (HLI)$12.9B
Daiwa Securities Group (DSEEY)$9.2B
Globe Life (GL)$9.2B
XP (XP)$9.2B
Brookfield Wealth Solutions (BNT)$8.3B
SouthState (SSB)$8B
StepStone Group (STEP)$7.5B
Jackson Financial (JXN)$7.3B
Freedom Holding (FRHC)$7.1B
Upstart Holdings (UPST)$6.5B
Lazard (LAZ)$6.2B
Blue Owl Capital (OBDC)$5.9B
Virtu Financial (VIRT)$5.7B
Rithm Capital (RITM)$5.5B
Core Scientific (CORZ)$4.6B
AXOS FINANCIAL, INC (AX)$4.5B
Euronet Worldwide (EEFT)$4.4B
PJT Partners (PJT)$3.7B
Community Financial System (CBU)$3.6B
Cleanspark (CLSK)$3.6B